Verana Health Launches Qdata Module for Thyroid Eye Disease Research

Verana Health has introduced its Qdata Thyroid Eye Disease (TED) module, a new addition to its suite of data solutions, featuring a comprehensive dataset derived from over 250,000 de-identified patients. This module is designed to enhance the extraction of diagnoses from clinical notes within electronic health records, providing crucial insights into Thyroid Eye Disease.

Utilizing IRIS Registry Data for Enhanced Insights

The Qdata TED module utilizes exclusive data from the American Academy of Ophthalmology’s IRIS Registry (Intelligent Research in Sight). Verana Health highlights the module’s capability to offer clinical development, health economics and outcomes research (HEOR), and medical affairs teams unparalleled insights into a clinically-validated population. This marks a significant advancement in the study and treatment of Thyroid Eye Disease, a condition known for its complexity.

Verana Health, which has access to a real-world data network of 90 million de-identified patients through more than 20,000 clinicians from its three exclusive data partnerships, announced that additional key variables will soon enhance the module. These additions include the designation of TED severity—categorized as mild, moderate-to-severe, and sight-threatening—and Clinical Activity Score (CAS).

CEO’s Perspective on the Impact of Real-World Data

Sujay Jadhav, CEO of Verana Health, emphasized the importance of this development in a press release. “Thyroid Eye Disease is diagnosed in roughly 1 million Americans each year and severely diminishes quality of life. There’s a critical unmet need for focused research and innovative treatment approaches for this condition, and real-world evidence can provide a catalyst for breakthroughs in disease management and therapeutic efficacy for this population, which can be challenging to identify,” Jadhav stated.

In addition to the Qdata TED module, Verana Health has recently developed the Qdata Dry Eye Disease (DED) module, also derived from the American Academy of Ophthalmology IRIS Registry. This module includes extensive data on specific tests like tear break-up time and Schirmer’s test results, offering deeper insights beyond what standard diagnostic codes can provide. This continuous expansion of data modules underscores Verana Health’s commitment to enhancing ophthalmologic research and treatment capabilities through the power of real-world data.

About Thyroid Eye Disease

Thyroid Eye Disease (TED) is an autoimmune condition often associated with thyroid dysfunction, particularly hyperthyroidism and Graves' disease. It primarily affects the muscles and fatty tissues around the eyes, leading to inflammation and swelling that can cause a range of symptoms. These include bulging eyes, dry and irritated eyes, redness, and discomfort. In severe cases, TED can lead to more serious complications such as double vision or even vision loss due to optic nerve compression. The disease's progression can vary significantly, and while some patients experience only mild symptoms, others may undergo significant changes that impact their vision and overall quality of life.